🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-523845-90-00
Completed Phase I

Safety and Preliminary Efficacy of CTX112 in Adult Participants with Relapsed/Refractory Hematologic Autoimmune Disease

2025-523845-90-00 · tracked via the Priya Life Science EU tracker
Sponsor
CRISPR Therapeutics AG
Sponsor type
Pharmaceutical company
Therapeutic area
Hemic and Lymphatic Diseases
Decision date
12/03/2026
Enrollment target
76
Sites
Spain, Germany, France, Denmark, Italy, Netherlands

Condition studied

Relapsed/Refractory Hematologic Autoimmune Disease

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-523845-90-00 on CTIS ↗ ← All trials in the EU